UroGen Pharma (NASDAQ:URGN) Earns Buy Rating from HC Wainwright

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $55.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 457.24% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. D. Boral Capital restated a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a research report on Monday, March 10th. Scotiabank initiated coverage on shares of UroGen Pharma in a report on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 price objective on the stock. The Goldman Sachs Group dropped their price target on UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating for the company in a research report on Thursday, April 17th. Finally, LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $32.86.

UroGen Pharma Stock Performance

Shares of URGN opened at $9.87 on Monday. UroGen Pharma has a one year low of $8.94 and a one year high of $20.70. The company has a market capitalization of $454.95 million, a PE ratio of -3.13 and a beta of 0.80. The company’s fifty day moving average price is $10.43 and its 200 day moving average price is $11.09. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The firm had revenue of $24.57 million for the quarter, compared to the consensus estimate of $25.25 million. As a group, analysts expect that UroGen Pharma will post -3.12 earnings per share for the current year.

Insider Buying and Selling

In related news, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the completion of the transaction, the general counsel now directly owns 26,468 shares of the company’s stock, valued at $294,853.52. This trade represents a 21.80 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the sale, the insider now owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On UroGen Pharma

Several hedge funds have recently made changes to their positions in URGN. Toronto Dominion Bank bought a new stake in UroGen Pharma during the fourth quarter valued at about $18,628,000. Acorn Capital Advisors LLC bought a new position in shares of UroGen Pharma during the 4th quarter valued at about $16,149,000. Nantahala Capital Management LLC bought a new position in shares of UroGen Pharma during the 4th quarter worth approximately $14,608,000. Vestal Point Capital LP raised its stake in shares of UroGen Pharma by 307.5% during the 4th quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company’s stock worth $17,360,000 after purchasing an additional 1,230,000 shares in the last quarter. Finally, Rosalind Advisors Inc. acquired a new stake in UroGen Pharma during the 4th quarter valued at $9,266,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.